Skip to main content

Table 2 Effects of different PPARD rs2016520 genotypes in T2DM patients on clinical characteristics determined before and after nateglinide treatment

From: PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus

Parameters

PPARD rs2016520

P values

 

TT

TC + CC

N (male/femal)

 

35(24/11)

25(15/10)

0.493b

FPG (mmol/L)

Before

9.07 ± 2.63

8.19 ± 1.42

0.134

After

6.74 ± 1.36

6.57 ± 0.87222

0.579

DV

 − 2.32 ± 1.72

 − 1.61 ± 1.44

0.099

PPG (mmol/L)

Before

15.23 ± 2.78

12.90 ± 2.66

0.002

After

10.57 ± 1.71

10.31 ± 1.42

0.538

DV

 − 4.66 ± 2.70

 − 2.59 ± 2.13

0.002

FINS (mU/L)

Before

9.36 ± 5.93

9.13 ± 5.91

0.883

After

16.06 ± 15.72

11.32 ± 9.05

0.182

DV

6.70 ± 15.03

2.19 ± 10.33

0.201

PINS (mU/L)

Before

41.55 ± 30.72

36.23 ± 36.61

0.544

After

75.14 ± 54.71

63.29 ± 50.51

0.397

DV

33.59 ± 43.71

27.07 ± 29.25

0.519

HOMA-IR

Before

3.81 ± 2.65

2.72 ± 1.47

0.443

After

4.94 ± 4.94

3.34 ± 2.97

0.157

DV

1.12 ± 4.85

 − 0.01 ± 3.53

0.338

HOMA-B

Before

28.25 ± 16.60

25.22 ± 14.80

0.469

After

73.20 ± 42.81

50.74 ± 26.43

0.015

DV

44.95 ± 19.23

25.48 ± 15.93

0.000

HbA1c (%)

Before

8.58 ± 1.81

7.02 ± 1.60

0.221

After

6.58 ± 1.12

6.42 ± 0.80

0.543

DV

 − 1.87 ± 1.55

 − 1.60 ± 1.44

0.714

TG (mmol/L)

Before

2.19 ± 1.58

2.09 ± 0.92

0.782

After

1.90 ± 1.26

1.78 ± 0.83

0.690

DV

 − 0.29 ± 0.78

 − 0.31 ± 0.64

0.926

TC (mmol/L)

Before

4.67 ± 1.20

4.45 ± 0.88

0.906

After

4.74 ± 1.19

4.52 ± 0.87

0.439

DV

 − 0.29 ± 0.75

 − 0.55 ± 1.12

0.283

HDL-C (mmol/L)

Before

1.29 ± 0.45

1.31 ± 0.38

0.788

After

1.38 ± 0.41

1.64 ± 0.92

0.158

DV

0.09 ± 0.38

0.32 ± 0.87

0.183

LDL-C (mmol/L)

Before

2.79 ± 0.80

2.87 ± 0.78

0.720

After

2.75 ± 0.79

2.58 ± 0.67

0.364

DV

 − 0.04 ± 0.61

0.29 ± 0.57

0.110

  1. Abbreviations: FPG, fasting plasma glucose; PPG, postprandial plasma glucose; FINS, fasting serum insulin; PINS, postprandial serum insulin; HOMA-IR, homeostasis model assessment for insulin resistance; HOMA-B, homeostasis model assessment for beta cell function; HbA1c, hemoglobin A1c; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol
  2. Data are given as mean ± SD. P values represent statistical difference between different genotypes assessed by independent-samples t-tests. bP values are determined by the Pearson chi-square test. cP values are determined by the Kruskal–Wallis test
  3. DV, differential values (post-administration minus pre-administration)